Cantor Fitzgerald analyst Matthew Lillis maintained a Buy rating on Supernus Pharmaceuticals (SUPN) on December 6 and set a price target of $57. The company’s shares opened today at $37.34, close to its 52-week low of $34.90.
Supernus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $59.50, implying a 59.3% upside from current levels. In a report issued on November 21, SunTrust Robinson also maintained a Buy rating on the stock with a $57 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $61.25 and a one-year low of $34.90. Currently, Supernus Pharmaceuticals has an average volume of 600.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.
